ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
Emles at Home ETF

Emles at Home ETF (LIV)

15,725
0,00
(0,00%)
Fermé 22 Décembre 10:00PM
0,00
0,00
(0,00%)
Après les heures de négociation: -

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

Dernier
15,725
Prix Achat
-
Prix Vente
-
Volume échangé
-
0,00 Fourchette du Jour 0,00
0,00 Plage de 52 semaines 0,00
Clôture Veille
15,725
Ouverture
-
Dernière Transaction
Dernière heure de transaction
Volume moyen (3 m)
-
Volume financier
-
VWAP
-

LIV Dernières nouvelles

Emles Advisors Announces Closure of Six Funds

Emles Advisors Announces Closure of Six Funds PR Newswire NEW YORK, Sept. 16, 2022 NEW YORK, Sept. 16, 2022 /PRNewswire/ -- Due to the inability to attract sufficient investment assets and based...

Samaritan to Initiate Phase III Clinical Trial in Europe to Accelerate Development Timeline of Its HIV Oral Entry Inhibitor SP0

Samaritan Pharmaceuticals Inc. (AMEX:LIV): ? -- Trial Designed to Tackle HIV Drug Resistance (One or More of a Patient's Current HIV Drug Regime Stops Working Leading to a Lack of Treatment...

Samaritan Reports Positive Preliminary Results with ''Oral'' HIV Entry Inhibitor in Phase II 10-Day HIV Monotherapy Trial

Samaritan Pharmaceuticals Inc. (AMEX:LIV): ? -- Data Shows 0.4 log10 Difference Between the High-Dose and the Placebo Control Group ? -- Dose dependent relationship in the number of subjects...

Samaritan Files Provisional Patent to Support Promising New Type of Anti-cholesterol Drug SP-1000 and Cover Additional Claims;

Samaritan Pharmaceuticals Inc. (AMEX:LIV): ? -- Clears Clogged Arteries ? -- Raises HDL ? -- Reduces CK Enzyme Marker: Suggesting It Improves, Hypercholesterolemia-Related Heart Suffering...

Samaritan Starts Enrolling for Its PII Stage 2 (28 Day Monotherapy) Study of ''Oral'' Entry Inhibitor SP-01A

Samaritan Pharmaceuticals (AMEX:LIV): ? -- Completed Phase II Stage 1 (10 Day Monotherapy) ? -- Expect to Report Stage I Preliminary Results at Shareholders Meeting May 31st ? -- Expect...

SIS Foundation Driven to Drive Bio Future Bus So Kids Can Speed up Science Innovation; Only 17% of US Students Graduate with Sc

The Samaritan Foundation and Samaritan Pharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs, announced today on National DNA day, it is driven to raise money to bring its...

Bio 2006 Analysts Predict Small-Cap Biotechs to Outperform Large-Caps This Year

Samaritan Pharmaceuticals Inc. (AMEX:LIV) ? -- David W. Munno, Merrill Lynch VP of biotechnology, stated, "Large-cap biotech firms need some blockbuster products for meaningful growth which is...

LIV to Host Annual Shareholders Meeting

Samaritan Pharmaceuticals Inc. (AMEX:LIV) a developer of innovative drugs, announced today, its shareholders are invited to the Annual Shareholders Meeting on Wednesday, May 31, 2006 10 a.m. at...

Samaritan's Marketing Authorization Application For Amphocil Approved in Greece

Samaritan Pharmaceuticals, Inc. (AMEX:LIV) is pleased to announce that its subsidiary Samaritan Pharmaceuticals Europe, S.A. has received notification by the National Pharmaceuticals Organization...

Samaritan to Present Its Drugs and Diagnostics for Partnering at BIO 2006 Annual International Conference

Samaritan Pharmaceuticals Inc. (AMEX:LIV): ? -- PII/III HIV Oral Entry Inhibitor Drug ? -- Cardiovascular Drug SP-1000 ? -- Alzheimer's Drug SP-233 ? -- Alzheimer's Blood Diagnostic ?...

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10000000SP
40000000SP
120000000SP
260000000SP
520000000SP
1560000000SP
2600000000SP
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

Delayed Upgrade Clock